153 related articles for article (PubMed ID: 15464874)
1. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
[TBL] [Abstract][Full Text] [Related]
2. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
Lord R; Nair S; Schache A; Spicer J; Somaihah N; Khoo V; Pandha H
J Urol; 2007 Jun; 177(6):2136-40; discussion 2140. PubMed ID: 17509300
[TBL] [Abstract][Full Text] [Related]
3. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
4. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
[TBL] [Abstract][Full Text] [Related]
6. Palliative chemotherapy with trofosfamide in advanced prostate cancer.
Salminen EK; Sundström J; Nikkanen V
Anticancer Res; 2006; 26(1B):539-42. PubMed ID: 16739316
[TBL] [Abstract][Full Text] [Related]
7. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
[TBL] [Abstract][Full Text] [Related]
9. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
Glode LM; Barqawi A; Crighton F; Crawford ED; Kerbel R
Cancer; 2003 Oct; 98(8):1643-8. PubMed ID: 14534880
[TBL] [Abstract][Full Text] [Related]
10. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E
Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
[TBL] [Abstract][Full Text] [Related]
13. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
15. Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.
Nelius T; Rinard K; Filleur S
Cancer Treat Rev; 2011 Oct; 37(6):444-55. PubMed ID: 21277093
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Miyake H; Hara I; Yamazaki H; Eto H
Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
18. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
Azuma H; Sakamoto T; Kiyama S; Ubai T; Kotake Y; Inamoto T; Takahara K; Nishimura Y; Segawa N; Katsuoka Y
Am J Clin Oncol; 2008 Apr; 31(2):188-94. PubMed ID: 18391605
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
[TBL] [Abstract][Full Text] [Related]
20. A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).
Hervonen P; Lehtinen T; Tammela TL; Kellokumpu-Lehtinen P
J Exp Clin Cancer Res; 2002 Jun; 21(2):177-80. PubMed ID: 12148574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]